Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CTGF siRNA
- Development stage
- Phase 2
- Lead developer
- Limm Therapeutics
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Subcutaneous, Intradermal, Intralesional
01
Overview
CTGF siRNA refers to a class of small interfering RNA (siRNA) therapeutics designed to silence the expression of connective tissue growth factor (CTGF, also known as CCN2). CTGF is a matricellular protein that plays a central role in the signaling pathways leading to fibrosis, including the induction of extracellular matrix (ECM) components like collagen. By utilizing the RNA interference (RNAi) pathway, these drugs trigger the sequence-specific degradation of CTGF mRNA, thereby reducing protein levels and inhibiting fibrotic progression. Clinical applications include the treatment of hypertrophic scars, keloids, and various organ-specific fibroses (e.g., pulmonary or liver fibrosis). Notable examples include LEM-S401, which utilizes a nanoparticle delivery system, and RXI-109, a self-delivering siRNA.
- Other names
- CCN2 siRNACCN-2 siRNACCN 2 siRNAConnective tissue growth factor siRNA
02
Targets
CTGF (Connective tissue growth factor)
Beyond the preview
Go deeper on CTGF siRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CTGF siRNA.